View in Other Languages Asian Activities Report for December 16, 2011: Asahi Glass Co., Ltd. (TYO:5201) to Establish a New Cathode Materials Production and Sales Site in China 2011년 12월 16일 아시아 현장보고서: Asahi Glass Co., Ltd. (TYO:5201), 중국에서 양극재 생산판매시설 확보 예정 2011年12月16日亚洲活动报告:旭硝子株式会社(TYO:5201)将在中国建立一处新的正极材料生产销售地点 アジア市場活動レポート 2011年12月16日:旭硝子 (TYO:5201) が中国において新たな正極材生産・販売拠点を設立予定 2011年12月16日亞洲活動報告:旭硝子株式會社(TYO:5201)將在中國建立一處新的正極材料生產銷售地點 
Asian Activities Report for December 16, 2011: Asahi Glass Co., Ltd. (TYO:5201) to Establish a New Cathode Materials Production and Sales Site in China
Asian Activities Report for December 16, 2011: Asahi Glass Co., Ltd. (TYO:5201) to Establish a New Cathode Materials Production and Sales Site in China

Sydney, Dec 16, 2011 AEST (ABN Newswire) - Asahi Glass Co., Ltd. (googlechartTYO:5201) will establish a new cathode materials production and sales site in China for lithium-ion batteries used in mobile devices and electronic vehicles. Asahi Glass will acquire a 51% interest in a Chinese cathode materials manufacturer, with production scheduled to start around April 2012. This will approximately double the current production capacity of Asahi Glass for cathode materials.

FUJIFILM Holdings Corporation (googlechartTYO:4901) has signed a definitive agreement to acquire all outstanding shares of SonoSite, Inc. (googlechartNASDAQ:SONO) for approximately US$995 million. This transaction will bring together the complementary strengths of Fujifilm's high-quality imaging technologies and SonoSite's pioneering point-of-care expertise and miniaturization capabilities, to drive the development of next generation medical imaging solutions.

Kobe Steel, Ltd. (googlechartTYO:5406) plans to increase the production capacity of its Chinese subsidiary which makes aluminum forgings for automotive suspensions. Kobe Steel will install an additional forging press and melting and casting equipment at its Chinese subsidiary. Total investment is anticipated to reach 4.5 billion yen and operations are expected to begin in March 2013.

Eisai Co., Ltd. (googlechartTYO:4523) has received approval from Health Canada for Halaven(TM), a novel anticancer agent for metastatic breast cancer patients who have previously received at least two chemotherapeutic regimens. Eisai will now begin preparations for the launch of Halaven(TM) with a view to commencing sales of the product in Canada during the fiscal year ending March 31, 2012.

Contact

Qiubei Fu
Asia Business News
Tel: +61-2-9247-4344
http://www.abnnewswire.net


ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 12) (Last 30 Days: 52) (Since Published: 13035) 

View in Other Languages 130351201810965100549949 (56021)

googlechart